RevitaLash® Cosmetics Launches New Length Define Tubing Mascara to Amplify Natural Lashes
Designed to amplify lashes, the ophthalmologist- and dermatologist-reviewed Length Define Tubing Mascara features a unique brush, which ensures even application of its smooth, non-flaking formula to create a lengthened, glossy, fanned out look to lashes. With a formula that's clinically tested, hypoallergenic, and cruelty-free, this innovative mascara featuring gentle tube technology that lengthens lashes while allowing for gentle and effortless removal with just warm water—no harsh rubbing required. Its smudge-resistant formula is also ideal for individuals with oily skin or those living in humid environments. In the brand's testing, their model experienced 300% longer lashes with Length Define.
"We are thrilled to introduce Length Define Tubing Mascara, which offers lash-nourishing benefits in an everyday mascara," said Lori Jacobus, President & Global CMO. "As the trend evolves toward less made-up looks, consumers are embracing the beauty of their natural lashes. Our new formula enhances the natural beauty of even the blondest lashes and lightest tips, while strengthening lashes to keep them in optimal condition."
Formulated with biotin and vitamin E, Length Define Tubing Mascara strengthens and protects against breakage while providing natural conditioning and antioxidant benefits to the lashes. Key ingredients like Myristoyl Pentapeptide-17, a powerful peptide and antioxidant, and panthenol, work together to enhance the appearance of lashes while maintaining hydration and delivering a healthy, radiant shine.
Length Define Tubing Mascara (5.0 mL) retails for $32.00 USD and is available globally at select physicians' offices, salons, spas, and specialty retailers and online at revitalash.com.
About RevitaLash® CosmeticsRevitaLash® Cosmetics is a worldwide leader in developing advanced lash, brow and hair beautification products. Established in 2006, the collection includes award-winning RevitaLash® Advanced Eyelash Conditioner and RevitaBrow® Advanced Eyebrow Conditioner, and is available in physician's offices, spas, salons, and specialty retailers across 70+ countries. A supporter of non-profit breast cancer initiatives, RevitaLash® Cosmetics donates a portion of proceeds to research and education initiatives, giving back to the breast cancer community year-round, not just in October. For information, visit www.revitalash.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/revitalash-cosmetics-launches-new-length-define-tubing-mascara-to-amplify-natural-lashes-302364887.html
SOURCE RevitaLash Cosmetics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
How South Korea's K-beauty industry is being hit by Trump tariffs
Cars and smartphones may rank among South Korea's biggest exports to the US, but few goods inspire a more devoted following than the Asian country's beauty products. K-beauty - a term that covers a wide range of skincare, makeup and cosmetics from South Korea - is lauded for its quality and value, driving soaring demand in recent years. The global appeal of South Korean culture has also helped propel the popularity of its cosmetics. US-based Pearl Mak tells the BBC that she was introduced to K-beauty products by her friends. South Korean serums are better-suited for her skin compared to some Western brands that tend to be more harsh, the 27-year-old graphic designer says. Now "95% of my skincare is made up of K-beauty products", she adds. Ms Mak is not alone in her preference for South Korean skincare brands. Americans spent as much $1.7bn (£1.3bn) on K-beauty products in 2024, according to industry estimates. That marks a more than 50% rise compared to the previous year. K-beauty products are often more attractively priced than their Western counterparts - but also feature ingredients that are not as commonly found in the West - from heartleaf to snail mucin. US President Donald Trump has now imposed a 15% import tax on South Korean goods traded between Seoul and Washington. It's less than the 25% levy that Trump had threatened, but many consumers are not taking any chances. The rise of Korean make-up in the West 'Flowerboys' and the appeal of 'soft masculinity' US K-beauty retailer Santé Brand saw orders spike by nearly 30% in April, right after Trump unveiled sweeping US import taxes on most of the world. "When the tariff announcements hit, customers got strategic with how they were going to weather the storm," Santé Brand's founder Cheyenne Ware told the BBC. "Consumers are preparing against the uncertainty." Another K-beauty retailer, Senti Senti, has been ordering more products since Trump started his tariff threats, says manager Winnie Zhong. This week, she received alerts from suppliers urging retailers to "stock up before tariffs". Both retailers said prices of K-beauty products are likely to increase as the levies push up costs across the industry. "Anyone telling you prices will stay flat through the next two years is naive," says Ms Ware. Prices are bound to rise, especially for smaller sellers of beauty products on platforms like Amazon, who operate with slim profit margins, economist Munseob Lee from the University of California San Diego says. Despite higher prices, the global popularity of South Korean culture means K-beauty products are likely to remain in demand in the US, he says. "Casual buyers might be turned off by the higher price, but fans won't find an easy substitute." Ms Zhong agrees. She thinks customers will still want to buy K-beauty products but price rises may mean they purchase fewer items than before. Higher prices are unlikely to stop Ms Mak buying her favourite products. "It depends on how much the price shoots up, but as of now, I am willing to pay more to purchase the same products," she says. 'No easy substitute' Big K-beauty brands are in a much better position to absorb the cost of tariffs than their smaller rivals, says South Korea-based business consultant Eyal Victor Mamou. These larger companies will be able to avoid major price rises for their customers as they have higher profit margins, he says. But smaller K-beauty firms that make their products in South Korea will struggle to keep a lid on costs, Mr Mamou adds. "It will take some time to take effect since most goods being sold in the short-run have already been commissioned at current prices, but we'll see it play out soon." In recent days, President Trump has struck deals with Japan and the European Union that will see their exports to the US subject to the same 15% tariffs as South Korea. That means countries that are home to some of the world's biggest cosmetics brands face the same levies as the K-beauty industry. Central to Trump's trade policies is his ambition to see more goods being made in America. But it's yet to be seen whether or not this will mean US buyers switch to American beauty products. Ms Mak says she doesn't see US-made products as attractive alternatives. "I do search for American-made alternatives often, but I have yet to find any that are as effective as the ones I use. So I wouldn't go for American products yet." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
5 hours ago
- Business Upturn
HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE:HIMS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025, both dates inclusive (the 'Class Period'). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Additionally, the Complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material facts, including that: (1) the communication between Hims and the pharmaceutical company Novo Nordisk A/S ('Novo') would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers; (2) Novo approved of Hims' offerings of compounded semaglutide products under the 'personalization' exception; (3) branded Wegovy would be offered alongside compounded semaglutide options on the Hims platform, thereby expanding user choice; and (4) Defendants made positive statements abou the Novo partnership and Hims users' ongoing access to Wegovy alongside compounded semaglutide products. If you purchased or otherwise acquired Hims & Hers shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Yahoo
7 hours ago
- Yahoo
Cleveland-Cliffs (CLF) Reports Q2 2025 Sales Decline to US$4934 Million
Cleveland-Cliffs recently faced challenges as their second-quarter 2025 earnings revealed sales declined to USD 4,934 million, while registering a net loss of USD 483 million compared to a modest net income last year. Despite these disappointing financial results, Cleveland-Cliffs's share price rose by 15% over the past month. This performance unfolded against the backdrop of a broader market that saw similar gains in July, although markets experienced a downturn due to economic concerns fueled by weak U.S. jobs data and renewed tariff policies. The company's operational struggles might have tempered the overall positive market momentum. We've identified 3 risks with Cleveland-Cliffs (at least 1 which is a bit unpleasant) and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent earnings report highlighting Cleveland-Cliffs' net loss of US$483 million amidst sales of US$4.93 billion presents a challenging landscape for the company. Despite this, shares have climbed 15% in the past month, reflecting broader market trends, though these gains might be vulnerable to ongoing economic uncertainties, such as the U.S. jobs data concerns. Addressing this financial strain is crucial as Cleveland-Cliffs navigates its reliance on U.S. steel tariffs and OEM reshoring, central to its growth narrative. Over a longer five-year period, Cleveland-Cliffs' total shareholder return, encompassing both share price appreciation and dividends, marked an impressive increase of 83.58%. This growth sharply contrasts with the company's recent underperformance against the US Metals and Mining industry over the past year. The industry saw returns of 13.4%, surpassing Cleveland-Cliffs' performance during the same one-year period. Future revenue and earnings projections are aligned with anticipated benefits from reshoring and tariff protections, yet the magnitude of the recent loss highlights potential vulnerabilities. Analysts anticipate the revenue will rise, with margins eventually reaching profitability. However, any shifts in trade policies or market conditions could alter these forecasts. With the current share price at US$10.06, close to the target of US$10.99, the upward movement suggests market confidence, yet analysts see limited upside relative to the target, indicating cautious optimism about hitting expected milestones. According our valuation report, there's an indication that Cleveland-Cliffs' share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CLF. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
